IQVIA Holdings Inc. (NYSE:IQV) Position Lessened by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% in the 4th quarter, Holdings Channel.com reports. The fund owned 5,230 shares of the medical research company’s stock after selling 168 shares during the quarter. Atria Wealth Solutions Inc.’s holdings in IQVIA were worth $1,210,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IQV. Commonwealth Equity Services LLC raised its holdings in shares of IQVIA by 3.6% during the third quarter. Commonwealth Equity Services LLC now owns 20,753 shares of the medical research company’s stock worth $4,083,000 after acquiring an additional 726 shares in the last quarter. Pinnacle Associates Ltd. raised its holdings in shares of IQVIA by 65.6% during the third quarter. Pinnacle Associates Ltd. now owns 1,678 shares of the medical research company’s stock worth $330,000 after acquiring an additional 665 shares in the last quarter. Raymond James & Associates raised its holdings in IQVIA by 4.4% during the third quarter. Raymond James & Associates now owns 832,515 shares of the medical research company’s stock valued at $163,797,000 after buying an additional 35,448 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in IQVIA by 6.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 532,369 shares of the medical research company’s stock valued at $104,744,000 after buying an additional 30,403 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its holdings in IQVIA by 6.4% during the third quarter. Stratos Wealth Partners LTD. now owns 6,739 shares of the medical research company’s stock valued at $1,326,000 after buying an additional 404 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of IQVIA stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the transaction, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Up 0.5 %

IQV stock opened at $232.89 on Thursday. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market cap of $42.27 billion, a PE ratio of 31.95, a price-to-earnings-growth ratio of 2.24 and a beta of 1.52. The business’s 50-day simple moving average is $245.07 and its 200 day simple moving average is $223.85. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The company had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.54 earnings per share. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Barclays raised their target price on IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Evercore ISI raised their target price on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Truist Financial raised their price target on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, SVB Leerink assumed coverage on IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $259.43.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.